125 related articles for article (PubMed ID: 18092815)
1. The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.
Coman RM; Robbins AH; Fernandez MA; Gilliland CT; Sochet AA; Goodenow MM; McKenna R; Dunn BM
Biochemistry; 2008 Jan; 47(2):731-43. PubMed ID: 18092815
[TBL] [Abstract][Full Text] [Related]
2. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
4. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
[TBL] [Abstract][Full Text] [Related]
5. Protease inhibition in African subtypes of HIV-1.
Velázquez-Campoy A; Vega S; Fleming E; Bacha U; Sayed Y; Dirr HW; Freire E
AIDS Rev; 2003; 5(3):165-71. PubMed ID: 14598565
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
Krauchenco S; Martins NH; Sanches M; Polikarpov I
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):638-45. PubMed ID: 18825538
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
[TBL] [Abstract][Full Text] [Related]
8. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
9. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
[TBL] [Abstract][Full Text] [Related]
10. Structural and energetic analysis on the complexes of clinically isolated subtype C HIV-1 proteases and approved inhibitors by molecular dynamics simulation.
Matsuyama S; Aydan A; Ode H; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2010 Jan; 114(1):521-30. PubMed ID: 20055526
[TBL] [Abstract][Full Text] [Related]
11. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
Ode H; Matsuyama S; Hata M; Hoshino T; Kakizawa J; Sugiura W
J Med Chem; 2007 Apr; 50(8):1768-77. PubMed ID: 17367119
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
14. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
15. Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.
Ode H; Matsuyama S; Hata M; Neya S; Kakizawa J; Sugiura W; Hoshino T
J Mol Biol; 2007 Jul; 370(3):598-607. PubMed ID: 17524421
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.
Bessong PO
Trop Med Int Health; 2008 Feb; 13(2):144-51. PubMed ID: 18304259
[TBL] [Abstract][Full Text] [Related]
17. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.
Holguín A; Suñe C; Hamy F; Soriano V; Klimkait T
J Clin Virol; 2006 Aug; 36(4):264-71. PubMed ID: 16765636
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia.
Batista PR; Wilter A; Durham EH; Pascutti PG
Cell Biochem Biophys; 2006; 44(3):395-404. PubMed ID: 16679526
[TBL] [Abstract][Full Text] [Related]
19. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
20. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]